Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 4/20 | 0.61 |
| ▸ | CTSB | P07858 | 4/20 | 0.61 |
| ▸ | CTSS | P25774 | 3/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25286907 | 1.00 | MEN1 (0.61) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL24029390 | 0.91 | MEN1 (0.62) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL23836483 | 0.89 | MEN1 (0.63) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL31197711 | 0.89 | MEN1 (0.63) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL24208602 | 0.88 | TAS1R3 (0.69) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL23824277 | 0.88 | MEN1 (0.67) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL28764917 | 0.88 | TAS1R3 (0.69) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL24113057 | 0.88 | MEN1 (0.64) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL23824273 | 0.88 | MEN1 (0.67) | MEN1KMT2ARCE1CTSLCTSB | |
| SCHEMBL29393963 | 0.88 | MEN1 (0.67) | MEN1KMT2ARCE1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | HOFFMANN-LA ROCHE INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116438160-A | Carbamoyl compounds for the treatment of viral infections | 豪夫迈·罗氏有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022043374-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060333-B2 | Aminocarbamoyl compounds for the treatment of viral infections | SARS1, BCAT1, SLC1A5 | MEN1 2627/4885KMT2A 1583/4885RCE1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.